Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H13NO2 |
| Molecular Weight | 167.205 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCCC1=CC(O)=C(O)C=C1
InChI
InChIKey=NGKZFDYBISXGGS-UHFFFAOYSA-N
InChI=1S/C9H13NO2/c1-10-5-4-7-2-3-8(11)9(12)6-7/h2-3,6,10-12H,4-5H2,1H3
| Molecular Formula | C9H13NO2 |
| Molecular Weight | 167.205 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Epinine or deoxyepinephrine is an active form of Ibopamine, which is used as a cardiovascular agent in congestive heart failure. Epinine is a stimulant of alpha-adrenoceptor activities: alpha-1 and alpha-2. Experiments on pig’s eyes have shown that epinine can be a promising candidate substance for intraoperative (e.g., cataract surgery) intracameral use in humans.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P08913 Gene ID: 150.0 Gene Symbol: ADRA2A Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. | 1993-06 |
|
| Development of dopaminergic drugs for the chronic treatment of congestive heart failure. | 1990 |
|
| Cardiovascular and renal action of dopaminergic prodrugs. | 1989 |
|
| Effect of dopamine, ibopamine, and epinine on alpha- and beta-adrenoceptors in canine pulmonary circulation. | 1989 |
|
| Effect of ibopamine and the active metabolite epinine on the catecholamine content of rat hypothalamus and brainstem in vitro. | 1988-11 |
|
| [Mechanism of action of ibopamine: pharmacological effects of epinine and other metabolites]. | 1988-01 |
|
| Analysis of epinine and its metabolites in man after oral administration of its pro-drug ibopamine using high-performance liquid chromatography with electrochemical detection. | 1986-08-22 |
|
| Comparison of the cardiovascular actions of dopamine and epinine in the dog. | 1985-04 |
|
| Electrophysiological and mechanical studies of frog heart adrenoceptor stimulation by epinine. | 1981-12 |
|
| Comparison of the central effects of dopamine and epinine. | 1973 |
Patents
Sample Use Guides
SIM2055 (FOSOPAMINE) was administered at increasing doses (from 100 to 300 mg).
Route of Administration:
Oral
One hundred twelve eyes from newly slaughtered pigs were used. After pretreatment with 20 mg intracameral acetylcholine to give miosis, 0.15 mL epinine was given as an intracameral injection. The pupils were filmed during 90 seconds with a video camera connected to an operation microscope, and the mean pupil diameters were measured from the video recordings. In 37 additional eyes, 0.15 mL vehicle, 1.5% epinine was injected intracamerally, and the eyes were kept on ice overnight. Epinine had a significantly larger mydriatic effect than phenylephrine at equal concentrations.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:06:16 GMT 2025
by
admin
on
Mon Mar 31 20:06:16 GMT 2025
|
| Record UNII |
R7339QLN1C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
18243
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
501-15-5
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
DEOXYEPINEPHRINE
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
4382
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
100000170833
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
DTXSID10198205
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
SUB185013
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
m4174
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB13917
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
R7339QLN1C
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY | |||
|
207-919-8
Created by
admin on Mon Mar 31 20:06:16 GMT 2025 , Edited by admin on Mon Mar 31 20:06:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Has 0.78 relative activity
EC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
